Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
This study has been completed.
Sponsor:
AstraZeneca
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01156246
First received: June 28, 2010
Last updated: May 31, 2012
Last verified: May 2012
| Tracking Information | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | June 28, 2010 | |||||||||
| Last Updated Date | May 31, 2012 | |||||||||
| Start Date ICMJE | June 2010 | |||||||||
| Primary Completion Date | August 2010 (final data collection date for primary outcome measure) | |||||||||
| Current Primary Outcome Measures ICMJE |
To assess the effect of food on the pharmacokinetics of dapagliflozin and metformin. [ Time Frame: Serial PK sampling will be done on Days 1-4 at visit 2 and 3. ] [ Designated as safety issue: No ] primary - single dose Cmax, AUCinf, AUC(0-t) of dapagliflozin and metformin.. secondary - single dose tmax, t1/2 of dapagliflozin and metformin |
|||||||||
| Original Primary Outcome Measures ICMJE | Same as current | |||||||||
| Change History | Complete list of historical versions of study NCT01156246 on ClinicalTrials.gov Archive Site | |||||||||
| Current Secondary Outcome Measures ICMJE |
To examine the safety and tolerability of the fixed-dose combination tablet of dapagliflozin and metformin. [ Time Frame: ECG at screening and follow-up. BP/pulse at screening, once daily during residential period and at follow-up. Clinical chemistry, haematology, and urine analyses at screening, day-1, day 4, and at follow-up. ] [ Designated as safety issue: Yes ] Vital signs (blood pressure and heart rate), electrocardiogram, laboratory safety data (clinical chemistry, haematology and urinalysis), adverse events. |
|||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | |||||||||
| Current Other Outcome Measures ICMJE | Not Provided | |||||||||
| Original Other Outcome Measures ICMJE | Not Provided | |||||||||
| Descriptive Information | ||||||||||
| Brief Title ICMJE | Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers | |||||||||
| Official Title ICMJE | An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/1000 mg) in Healthy Male and Female Volunteers | |||||||||
| Brief Summary | The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food. | |||||||||
| Detailed Description | Not Provided | |||||||||
| Study Type ICMJE | Interventional | |||||||||
| Study Phase | Phase 1 | |||||||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
|||||||||
| Condition ICMJE | Healthy | |||||||||
| Intervention ICMJE | Drug: Dapagliflozin/Metformin
oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3. |
|||||||||
| Study Arm (s) |
|
|||||||||
| Publications * | Not Provided | |||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
| Recruitment Information | ||||||||||
| Recruitment Status ICMJE | Completed | |||||||||
| Enrollment ICMJE | 18 | |||||||||
| Completion Date | August 2010 | |||||||||
| Primary Completion Date | August 2010 (final data collection date for primary outcome measure) | |||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||||||||
| Gender | Both | |||||||||
| Ages | 18 Years to 55 Years (Adult) | |||||||||
| Accepts Healthy Volunteers | Yes | |||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||||||||
| Listed Location Countries ICMJE | Sweden | |||||||||
| Removed Location Countries | ||||||||||
| Administrative Information | ||||||||||
| NCT Number ICMJE | NCT01156246 | |||||||||
| Other Study ID Numbers ICMJE | D1691C00005 | |||||||||
| Has Data Monitoring Committee | No | |||||||||
| Plan to Share Data | Not Provided | |||||||||
| IPD Description | Not Provided | |||||||||
| Responsible Party | AstraZeneca | |||||||||
| Study Sponsor ICMJE | AstraZeneca | |||||||||
| Collaborators ICMJE | Bristol-Myers Squibb | |||||||||
| Investigators ICMJE |
|
|||||||||
| Information Provided By | AstraZeneca | |||||||||
| Verification Date | May 2012 | |||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
||||||||||